Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective for obese patients with type 2 diabetes mellitus (T2DM) because they concomitantly target obesity and dysglycaemia. Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T2DM, we determined the impact of 6 months' GLP-1 RA therapy on intrahepatic lipid (IHL) in obese, T2DM patients with hepatic steatosis, and evaluated the inter-relationship between changes in IHL with those in glycosylated haemoglobin (HbA(1)c), body weight, and volume of abdominal visceral and subcutaneous adipose tissue (VAT and SAT). We prospectively studied 25 (12 male) patients, age 50±10 years, BMI 38.4±5.6 kg/m(2) (mean ± SD) with baseline IHL of 28.2% (16.5 to 43.1%) and HbA(1)c of 9.6% (7.9 to 10.7%) (median and interquartile range). Patients treated with metformin and sulphonylureas/DPP-IV inhibitors were given 6 months GLP-1 RA (exenatide, n = 19; liraglutide, n = 6). IHL was quantified by liver proton magnetic resonance spectroscopy ((1)H MRS) and VAT and SAT by whole body magnetic resonance imaging (MRI). Treatment was associated with mean weight loss of 5.0 kg (95% CI 3.5,6.5 kg), mean HbA(1c) reduction of 1·6% (17 mmol/mol) (0·8,2·4%) and a 42% relative reduction in IHL (-59.3, -16.5%). The relative reduction in IHL correlated with that in HbA(1)c (ρ = 0.49; p = 0.01) but was not significantly correlated with that in total body weight, VAT or SAT. The greatest IHL reduction occurred in individuals with highest pre-treatment levels. Mechanistic studies are needed to determine potential direct effects of GLP-1 RA on human liver lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the observed reduction in liver fat content (6.2%) in the GLP-1RA arm is similar to previous studies in people with MASLD,23,24”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with exenatide reduced liver steatosis [109,146,150] and when added to pioglitazone, an oral hypoglycemic and insulin sensitizing drug approved for the treatment of T2D that acts on nuclear peroxisome proliferator activated receptor-gamma (PPAR-γ) [147], potentiated the known action of pioglitazone in reducing hepatic fat [92].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [150]
In the citing paper
“Liraglutide promoted weight loss and beneficially altered the fat distribution by decreasing waist circumference, waist/hip ratio, and the amount of subcutaneous and visceral fat content and liver steatosis [145,150,152,155].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“GLP-1 acts through several distinct mechanisms including stimulation of glucose-dependent insulin secretion, inhibition of glucagon secretion, delay of gastric emptying and promotion of weight loss through central inhibition of appetite [1].”
BackgroundDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“A further possibility, consistent with the correlation we observed between effects on IHL and HBA1c, is that the effects on IHL are secondary to improved glucose tolerance, with reduced hyperinsulinemia (and perhaps reduced hyperglycaemia), reducing the increased rate of hepatocyte lipogenesis characteristic of these…”
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089 · cited 1×
“NAFLD describes a disease spectrum with excessive deposition of fat within the liver (hepatic steatosis), which may be associated with inflammation, cell death, and fibrosis (non-alcoholic steatohepatitis, NASH), ultimately progressing to cirrhosis [3].”
BackgroundA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562 · cited 13×
“Reproducibility of MRI and MRS Analysis Volumetric analysis of adipose tissue content: the mean coefficient of variations (CoV) were determined as total body fat, 1–2%; total subcutaneous fat, 3–4%; abdominal subcutaneous fat, 1–3%; visceral fat, 6–8%.”
MethodInfluentialBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164 · cited 1×
“dietary intervention consisting of a 600 kcal diet, liver fat reduced by a total of 7065% [35].”
BackgroundPetersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Bugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., & Marchesini, G. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41583.x · Cited by 691 · cited 1×
“Treatment with metformin or glitazone (either rosiglitazone or pioglitazone) may also ameliorate NAFLD, with metabolic and histological improvement, predominantly through reduced steatosis and inflammation, with little effect on fibrosis [22–25].”
BackgroundMeasurement of intracellular triglyceride stores by H spectroscopy: validation in vivo
Szczepaniak, L. S., Babcock, E. E., Schick, F., Dobbins, R. L., Garg, A., Burns, D. K., McGarry, J. D., & Stein, D. T. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.5.e977 · Cited by 688 · cited 1×
“Fat quantification by H MRS has been validated against gold standard biochemical measurements [32].”
MethodTargher, G., Bertolini, L., Poli, F., Rodella, S., Scala, L., Tessari, R., Zenari, L., & Falezza, G. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3541 · Cited by 574 · cited 1×
“NAFLD has a high prevalence in patients with type 2 diabetes, diagnosed variously on the basis of abnormal liver biochemistry, ultrasonography [4], proton magnetic resonance spectroscopy (H MRS) or liver biopsy [5–7].”
BackgroundGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524 · cited 12×
“changes in other histological features [23,36].”
BackgroundInfluentialBugianesi, E., Pagotto, U., Manini, R., Vanni, E., Gastaldelli, A., de Iasio, R., Gentilcore, E., Natale, S., Cassader, M., Rizzetto, M., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2240 · Cited by 408 · cited 3×
“demonstrated that modest weight reduction (,8 kg) in patients with type 2 diabetes substantially reduced hepatic steatosis (by ,80%) and concomitantly improved hepatic insulin resistance [19,21].”
BackgroundResultSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study.
de Marco, R., Locatelli, F., Zoppini, G., Verlato, G., Bonora, E., & Muggeo, M. (1999) · Diabetes Care · doi:10.2337/diacare.22.5.756 · Cited by 405
Williamson, R. M., Price, J. F., Glancy, S., Perry, E., Nee, L. D., Hayes, P. C., Frier, B. M., Van Look, L. A. F., Johnston, G. I., Reynolds, R. M., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2229 · Cited by 391 · cited 2×
“NAFLD has a high prevalence in patients with type 2 diabetes, diagnosed variously on the basis of abnormal liver biochemistry, ultrasonography [4], proton magnetic resonance spectroscopy ((1)H MRS) or liver biopsy [5–7].”
BackgroundMethodTargher, G., Bertolini, L., Rodella, S., Zoppini, G., Lippi, G., Day, C., & Muggeo, M. (2008) · Diabetologia · doi:10.1007/s00125-007-0897-4 · Cited by 383
Targher, G., Marra, F., & Marchesini, G. (2008) · Diabetologia · doi:10.1007/s00125-008-1135-4 · Cited by 378
Lazo, M., Solga, S. F., Horska, A., Bonekamp, S., Diehl, A. M., Brancati, F. L., Wagenknecht, L. E., Pi-Sunyer, F. X., Kahn, S. E., Clark, J. M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0856 · Cited by 367 · cited 1×
“Current treatment of NAFLD is aimed at weight loss through lifestyle interventions involving diet and exercise [17–20].”
BackgroundBajaj, M., Suraamornkul, S., Piper, P., Hardies, L. J., Glass, L., Cersosimo, E., Pratipanawatr, T., Miyazaki, Y., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031315 · Cited by 358 · cited 1×
“The significant increase in serum total adiponectin concentration with GLP-1 RA therapy, consistent with previous data [17,19], maybe implicated in the mechanism by which liver fat is reduced.”
ResultKotronen, A., Juurinen, L., Tiikkainen, M., Vehkavaara, S., & Yki–Järvinen, H. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.021 · Cited by 339 · cited 1×
“This high prevalence is not simply explained by the high incidence of obesity in type 2 diabetes, as liver fat is increased in patients with type 2 diabetes compared with age- and BMI-matched healthy controls [5,8–11] but is important for several reasons.”
BackgroundGlucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., & Fishman, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.032 · Cited by 328
Thomas, E. L., Hamilton, G., Patel, N., O’Dwyer, R., Doré, C. J., Goldin, R. D., Bell, J. D., & Taylor-Robinson, S. D. (2005) · Gut · doi:10.1136/gut.2003.036566 · Cited by 317
Self-citationJendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312 · cited 1×
“In patients treated with GLP-1 receptor agonists (GLP-1 RA), the weight loss is predominantly associated with a reduction in adipose tissue [2] although the inter-relationships between the relative amounts of visceral, subcutaneous and hepatic fat loss remain unknown.”
BackgroundBajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L. J., Pratipanawatr, W., Glass, L., Cersosimo, E., Miyazaki, Y., & DeFronzo, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1364 · Cited by 290 · cited 1×
“changes in other histological features [23,36].”
Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279 · cited 1×
“As for GLP-1 RAs, Buse et al demonstrated that 2 years exenatide therapy was associated with significant improvement in abnormal liver transaminases, biomarkers of hepatocyte injury most commonly reflecting NAFLD [26].”
BackgroundBenefits of lifestyle modification in NAFLD
Harrison, S. A., & Day, C. P. (2007) · Gut · doi:10.1136/gut.2006.112094 · Cited by 240 · cited 1×
“Current treatment of NAFLD is aimed at weight loss through lifestyle interventions involving diet and exercise [17–20].”
BackgroundKotronen, A., Juurinen, L., Hakkarainen, A., Westerbacka, J., Cornér, A., Bergholm, R., & Yki-Järvinen, H. (2008) · Diabetes Care · doi:10.2337/dc07-1463 · Cited by 196 · cited 2×
“This high prevalence is not simply explained by the high incidence of obesity in type 2 diabetes, as liver fat is increased in patients with type 2 diabetes compared with age- and BMI-matched healthy controls [5,8–11] but is important for several reasons.”
BackgroundTargher, G., Bertolini, L., Padovani, R., Poli, F., Scala, L., Tessari, R., Zenari, L., & Falezza, G. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01817.x · Cited by 173
Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care · doi:10.2337/dc09-2361 · Cited by 161 · cited 1×
“However, a lack of significant correlation between adiponectin increase and any measure of body composition is consistent with previous reports [33].”
ResultIncretin mimetics as a novel therapeutic option for hepatic steatosis
Tushuizen, M. E., Bunck, M. C. M., Pouwels, P. J. W., van Waesberghe, J. H. T., Diamant, M., & Heine, R. J. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01315.x · Cited by 127 · cited 1×
“In a single case report, in which 44 weeks of exenatide was associated with a similar reduction in body weight as we observed, a 4 kg absolute reduction or a 5% relative reduction, (1)H MRS-measured IHCL declined by 73% (from 16% to 4%) [27].”
BackgroundEffects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes
Sathyanarayana, P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., & Bajaj, M. (2011) · Obesity · doi:10.1038/oby.2011.152 · Cited by 124
Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: A case series
Kenny, P. R., Brady, D. E., Torres, D. M., Ragozzino, L., Chalasani, N., & Harrison, S. A. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.363 · Cited by 106 · cited 2×
“This is supported by a recent case series of 8 patients with type 2 diabetes and biopsy-proven NAFLD who underwent liver biopsies before and after 28 weeks of exenatide therapy, in 3 of whom liver histology improved [28].”
BackgroundRatziu, V., Caldwell, S. H., & Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.24042 · Cited by 79 · cited 1×
“T2DM patients with NAFLD have been suggested as a population worthy of further clinical study to examine the role of insulin sensitizers and related drugs in ameliorating NAFLD [22].”
BackgroundHattersley, J. G., Möhlig, M., Roden, M., Arafat, A. M., von Loeffelholz, C., Nowotny, P., Machann, J., Hierholzer, J., Osterhoff, M. A., Khan, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039029 · Cited by 20 · cited 1×
“validated a simple index of hepatic insulin resistance using serum glucose and insulin against the gold standard methods using stable isotopes and clamps [38].”
MethodHypothyroidism in a patient with non-alcoholic fatty liver disease
Gardner, C., Richardson, P., Wong, C., Polavarapu, N. K., Kemp, G. J., & Cuthbertson, D. J. (2011) · BMJ · doi:10.1136/bmj.c7199 · Cited by 19 · cited 1×
“5T Siemens Symphony scanner (Siemens Medical Solutions, Erlangen, Germany) at a single site, the University of Liverpool Magnetic Resonance and Image Analysis Research Centre, as previously described [30] A single experienced radiographer (VLA) performed all scans.”
MethodSelf-citation
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Takaki, A., Kawai, D., & Yamamoto, K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141020704 · Cited by 447
“patients with NAFLD caused a reduction in intrahepatic lipid content that correlated with diabetic control [96].”
Background
Metadata
- Authors
- Cuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., Pirmohamed, M., & Kemp, G. J.
- Affiliations
- University of Liverpool (GB)
- Aintree University Hospital (GB)
- Royal Liverpool University Hospital (GB)
- Countess of Chester Hospital (GB)
- Imperial College London (GB)
- Corresponding author
- Cuthbertson, Daniel J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-12-06
- Volume
- 7
- Issue
- 12
- Pages
- e50117
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3516516
- OpenAlex
- W2041468536
- Cited by
- 226
- References
- 37
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 9 · 2023: 12 · 2022: 15 · 2021: 15 · 2020: 22 · 2019: 12 · 2018: 19 · 2017: 14 · 2016: 22 · 2015: 18 · 2014: 35 · 2013: 13
- FWCI
- 16.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- WestminsterResearch (University of Westminster) (acceptedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- European Foundation for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, obesity, non-alcoholic fatty liver disease, intrahepatic lipid, hepatic steatosis, glycemic control, HbA1c, exenatide, liraglutide, visceral adipose tissue, subcutaneous adipose tissue, weight loss
- MeSH terms
- Liraglutide, Exenatide, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fatty Liver, Female, Humans, Hypoglycemic Agents, Liver, Male, Middle Aged, Obesity, Peptides, Prospective Studies, Venoms, Weight Loss, Body Mass Index, Adiposity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.